Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: Cases series and review of the literature

Clinical Rheumatology

Volumn 32, Issue 12, 2013, Pages 1827-1832

  Novikov, P I ^a   Smitienko, I O ^b   Moiseev, S V ^a,c  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^c NONE   (Russian Federation)

Author keywords

Infliximab; Takayasu's arteritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; INFLIXIMAB; INTERLEUKIN 6; PREDNISONE;

ADULT; ALLERGIC REACTION; AORTA ARCH SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; TREATMENT DURATION; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; POSITRON-EMISSION TOMOGRAPHY; REMISSION INDUCTION; TAKAYASU ARTERITIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890425535     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2380-6     Document Type: Review

References (37)

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1-11
2. Mason JC (2010) Takayasu arteritis - advances in diagnosis and management. Nat Rev Rheumatol 6:406-415
3. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, Cacoub P, Saadoun D (2012) Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11:678-684
4. Mevorach D, Leibowitz G, Brezis M, Raz E (1992) Induction of remission in a patient with Takayasu's arteritis by low dose pulses of methotrexate. Ann Rheum Dis 51:904-905
5. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30:1793-1798
6. Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu's arteritis and its therapy. Ann Intern Med 103:121-126
7. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578-582
8. de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI (2012) Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41:227-230
9. Kötter I, Henes JC, Wagner AD, Loock J, Gross WL (2012) Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 30:S114-S129
10. Schäfer VS, Zwerina J (2012) Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 24:31-37
11. Maksimowicz-McKinnon K, Hoffman GS (2007) Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 33:777-786
12. Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34-38
13. Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 45:545-548
14. Tripathy NK, Gupta PC, Nityanand S (2006) High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 118:154-158
15. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 64:1079-1083
16. Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, Federici L, Berthier S, Fiessinger JN, Godeau B, Marie I, Guillevin L, Hamidou M, Fain O, Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne (2012) Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 51:882-886
17. Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, Bombardieri S, Punzi L, De Vita S (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30:922-928
18. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567-1569
19. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129-1134
20. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919-929
21. Blockmans D (2011) PET in vasculitis. Ann N Y Acad Sci 1228:64-70
22. Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, Park MC, Lee JD, Lee SK, Park YB (2012) The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum 64:866-875
23. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA, on behalf of the Indian Rheumatology Vasculitis (IRAVAS) group (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). doi: 10.1093/rheumatology/ket128
24. Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54:S155-S163
25. Wen D, Du X, Ma CS (2012) Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol 31:462-473
26. Direskeneli H, Aydin SZ, Merkel PA (2011) Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol 29:S86-S91
27. Pipitone N, Olivieri I, Salvarani C, Italian Society of Rheumatology (2012) Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 30:S139-S161
28. Nunes G, Neves FS, Melo FM, de Castro GR, Zimmermann AF, Pereira IA (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:291-298
29. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296-2304
30. Langford CA (2008) Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases. Nat Clin Pract Rheumatol 4:364-370
31. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75-79
32. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61-67
33. Unizony S, Stone JH, Stone JR (2013) New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 25:3-9
34. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58:1197-1200
35. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720-1729
36. Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L (2012) Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol 30:S90-S93
37. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156